Significance of Des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma

American Journal of Transplantation

Volumn 9, Issue 10, 2009, Pages 2362-2371

  Fujiki, M ^a   Takada, Y ^b   Ogura, Y ^b   Oike, F ^b   Kaido, T ^b   Teramukai, S ^c   Uemoto, S ^b  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Hepatocellular carcinoma; Histological; Living donor transplantation; Marker; Selection

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; STEROID; TACROLIMUS;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; DONOR SELECTION; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER NODULE; LIVER TRANSPLANTATION; LIVING DONOR; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROTEIN PRECURSORS; PROTHROMBIN; ROC CURVE; SURVIVAL ANALYSIS;

EID: 70349213817     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02783.x     Document Type: Article

References (42)

1. Liebman HA, Furie BC, Tong MJ et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984 310 : 1427 1431.
2. Fujiyama S, Morishita T, Hashiguchi O, Sato T. Plasma abnormal prothrombin (des-gamma-carboxy prothrombin) as a marker of hepatocellular carcinoma. Cancer 1988 61 : 1621 1628.
3. Marrero JA, Su GL, Wei W et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003 37 : 1114 1121.
4. Suehiro T, Matsumata T, Itasaka H, Taketomi A, Yamamoto K, Sugimachi K. Des-gamma-carboxy prothrombin and proliferative activity of hepatocellular carcinoma. Surgery 1995 117 : 682 691.
5. Suehiro T, Sugimachi K, Matsumata T, Itasaka H, Taketomi A, Maeda T. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein. Cancer 1994 73 : 2464 2471.
6. Koike Y, Shiratori Y, Sato S et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: A prospective analysis of 227 patients. Cancer 2001 91 : 561 569.
7. Okuda H, Nakanishi T, Takatsu K et al. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma. Cancer 2000 88 : 544 549.
8. Shah SA, Cleary SP, Wei AC et al. Recurrence after liver resection for hepatocellular carcinoma: Risk factors, treatment, and outcomes. Surgery 2007 141 : 330 339.
9. Hakamada K, Kimura N, Miura T et al. Des-gamma-carboxy prothrombin as an important prognostic indicator in patients with small hepatocellular carcinoma. World J Gastroenterol 2008 14 : 1370 1377.
10. Shimada M, Takenaka K, Fujiwara Y et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma. Cancer 1996 78 : 2094 2100.
11. Hamamura K, Shiratori Y, Shiina S et al. Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein. Cancer 2000 88 : 1557 1564.
12. Nagaoka S, Yatsuhashi H, Hamada H et al. The des-gamma-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma. Cancer 2003 98 : 2671 2677.
13. Nanashima A, Morino S, Yamaguchi H et al. Modified CLIP using PIVKA-II for evaluating prognosis after hepatectomy for hepatocellular carcinoma. Eur J Surg Oncol 2003 29 : 735 742.
14. Kim do Y, Paik YH, Ahn SH et al. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. Oncology 2007 72 (Suppl 1 52 57.
15. Kishi K, Sonomura T, Mitsuzane K et al. Time courses of PIVKA-II and AFP levels after hepatic artery embolization and hepatic artery infusion against hepatocellular carcinoma: Relation between the time course and tumor necrosis. Radiat Med 1992 10 : 189 195.
16. Minakuchi K, Murata K, Kaminoh T et al. Clinical evaluation of serum alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) levels in patients with hepatocellular carcinoma following interventional radiology. Radiat Med 1993 11 : 231 236.
17. Tateishi R, Shiina S, Yoshida H et al. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology 2006 44 : 1518 1527.
18. Kobayashi M, Ikeda K, Kawamura Y et al. High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer 2009 115 : 571 580.
19. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996 334 : 693 699.
20. Duffy JP, Vardanian A, Benjamin E et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: A 22-year experience with 467 patients at UCLA. Ann Surg 2007 246 : 502 509 discussion 509 511.
21. Onaca N, Davis GL, Goldstein RM, Jennings LW, Klintmalm GB. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: A report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl 2007 13 : 391 399.
22. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the scientific registry of transplant recipients database. Hepatology 2009 49 : 832 838.
23. Mazzaferro V, Llovet JM, Miceli R et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory analysis. Lancet Oncol 2009 10 : 35 43.
24. Marsh JW, Dvorchik I, Bonham CA, Iwatsuki S. Is the pathologic TNM staging system for patients with hepatoma predictive of outcome? Cancer 2000 88 : 538 543.
25. Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 2001 33 : 1394 1403.
26. Shetty K, Timmins K, Brensinger C et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004 10 : 911 918.
27. Todo S, Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: Experience in Japan. Ann Surg 2004 240 : 451 459 discussion 459 461.
28. Zavaglia C, De Carlis L, Alberti AB et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol 2005 100 : 2708 2716.
29. Shimoda M, Ghobrial RM, Carmody IC et al. Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C. Liver Transpl 2004 10 : 1478 1486.
30. Parfitt JR, Marotta P, Alghamdi M et al. Recurrent hepatocellular carcinoma after transplantation: Use of a pathological score on explanted livers to predict recurrence. Liver Transpl 2007 13 : 543 551.
31. Lee SG, Hwang S, Moon DB et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl 2008 14 : 935 945.
32. Silva M, Moya A, Berenguer M et al. Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transpl 2008 14 : 1449 1460.
33. Takada Y, Ueda M, Ito T et al. Living donor liver transplantation as a second-line therapeutic strategy for patients with hepatocellular carcinoma. Liver Transpl 2006 12 : 912 919.
34. Ito T, Takada Y, Ueda M et al. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl 2007 13 : 1637 1644.
35. Harrell FE Jr., Lee KL, Mark DB. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996 15 : 361 387.
36. Tsuruta H, Bax L. Polychotomization of continuous variables in regression models based on the overall C index. BMC Med Inform Decis Mak 2006 6 : 41.
37. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982 143 : 29 36.
38. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983 148 : 839 843.
39. Takamori R, Wong L, Dang C, Wong L. Needle-tract implantation from hepatocellular cancer: Is needle biopsy of the liver always necessary? Liver Transpl 2000 6 : 67 72.
40. Khan KN, Yatsuhashi H, Yamasaki K et al. Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection. J Hepatol 2000 32 : 269 278.
41. Shirabe K, Itoh S, Yoshizumi T et al. The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol 2007 95 : 235 240.
42. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: Comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002 8 : 765 774.